Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS)One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational...